Tryptophan Kynurenine Pathway: Metabolic Architecture
Tryptophan (essential amino acid; ~1% dietary protein; precursor for serotonin, melatonin, kynurenines, NAD+, indoles) metabolism: >90% via the kynurenine pathway (KP; liver TDO2 (tryptophan 2,3-dioxygenase; constitutive; glucocorticoid/tryptophan-inducible; liver-specific; degrades excess tryptophan) and IDO1 (indoleamine 2,3-dioxygenase 1; extra-hepatic; plasmacytoid DCs/macrophages/endothelium; induced by IFN-γ, LPS/TLR4→NF-κB, IL-6, TNF-α); both enzymes: L-Trp + O2 → N-formylkynurenine (NFK) → arylformamidase → L-kynurenine (KYN)); <5% via serotonin (5-HT; TPH1/2 → 5-HTP → AADC) and melatonin branches. Kynurenine further metabolised to: (1) kynurenic acid (KA; kynurenine aminotransferase (KAT) II; astrocyte; neuroprotective; NMDA receptor antagonist; nicotinic acid receptor agonist; AhR ligand); (2) 3-hydroxykynurenine (3-HK; kynurenine hydroxylase/KMO; pro-oxidant; ROS generator; H2O2 production); (3) anthranilic acid (AA); (4) quinolinic acid (QUIN; quinolinate phosphoribosyltransferase → NAD+; also direct NMDA agonist → glutamate excitotoxicity → neuronal Ca2+ overload → apoptosis; elevated in depression, neuroinflammation, sepsis, HIV encephalitis). Kynurenine → AhR (aryl hydrocarbon receptor; nuclear receptor; KYN/KA/FICZ ligands → AhR:ARNT → CYP1A1/1B1/xenobiotic metabolism; also ID01 transcription positive feedback; Treg induction → immunosuppression; tumour immune escape).
Spirulina Mechanisms in Tryptophan/Kynurenine Pathway
IDO1 Suppression via NF-κB/IFN-γ Pathway
IDO1 (the critical enzyme for inflammation-induced tryptophan depletion; IDO1 transcription driven by: IFN-γ→JAK1/2→STAT1→GAS element in IDO1 promoter (primary); NF-κB (secondary; LPS/TNF-α→IKKβ→p65→κB sites in IDO1); IL-6→STAT3 (tertiary); IDO1 is heme-containing; Fe2+-haem at active site) is suppressed by spirulina at multiple levels: (1) NF-κB/IKKβ inhibition (−30–45% p65 nuclear translocation) → reduced NF-κB-driven IDO1 transcription; (2) IFN-γ downstream signal attenuation: phycocyanin reduces STAT1 Tyr701 phosphorylation in IFN-γ-stimulated macrophages (−20–30%); (3) IL-6 reduction (−25–40%) → STAT3-IDO1 transcription reduction. Net: KTR (kynurenine:tryptophan ratio; clinical biomarker of IDO1 activity; normal ~0.03; elevated in depression, COVID-19, cancer >0.1) reduction −20–35% in inflammatory models; serum tryptophan preservation +10–20% (more tryptophan available for TPH1/2-serotonin and melatonin synthesis).
Kynurenic Acid vs. Quinolinate Balance
The KYN branch point (3-hydroxykynurenine (3-HK) → 3-hydroxyanthranilic acid (3-HAA) → quinolinate (QUIN) via HAAO (3-hydroxyanthranilic acid oxidase); vs. KYN → KA (kynurenic acid) via KAT II (kynurenine aminotransferase II; astrocyte; PLP-dependent)) determines neurotoxic vs. neuroprotective kynurenine metabolism. Excess IDO1 flux (inflammatory conditions) drives more KYN → 3-HK → 3-HAA → QUIN (neurotoxic) relative to KYN → KA (neuroprotective). QUIN:KA ratio elevation is pathological (depression, ALS, Alzheimer's, HIV dementia). Spirulina B6 (pyridoxal phosphate; PLP; ~0.3 mg/100g; KAT II is PLP-dependent; B6 deficiency reduces KAT II activity → shifts KYN toward QUIN) provision supports KAT II activity (+10–15% KA production). Additionally, spirulina antioxidant ROS reduction (−30–45%) suppresses 3-HK-driven H2O2 generation (3-HK auto-oxidation → H2O2 → brain oxidative damage), and Nrf2 activators directly upregulate KYNU (kynureninase; B6-dependent; KYN → anthranilic acid → non-neurotoxic) providing a third metabolic escape route from QUIN accumulation.
AhR Ligand Competition: Phycocyanobilin and Polyphenol AhR Modulation
AhR (aryl hydrocarbon receptor; ligand-activated nuclear receptor/transcription factor; broad ligand specificity: TCDD (dioxin; canonical toxic; pM affinity), FICZ (6-formylindolo[3,2-b]carbazole; Trp photoproduct; nM), kynurenine/kynurenic acid (low-affinity; µM), phytochemicals; nuclear translocation: AhR + ARNT (AhR nuclear translocator) → DRE/XRE → CYP1A1/CYP1B1/AhRR + IDO1 (positive feedback); immunological AhR: Treg induction (KYN-AhR-FoxP3), Th17 induction (FICZ-AhR-IL-17); tumour AhR: IDO1/PD-L1 upregulation → T cell exhaustion) is engaged by spirulina components at multiple points: phycocyanobilin (linear tetrapyrrole; structural similarity to some endogenous indole-AhR ligands; moderate AhR partial agonist/antagonist at µM concentrations → competes with kynurenine for AhR → blunts immunosuppressive KYN-AhR-Treg axis); quercetin, kaempferol (AhR competitive antagonists; reduce DRE-luciferase reporter −20–30%; AhRR (AhR repressor) upregulation). Net: AhR-IDO1 positive feedback loop −15–25%; IDO1 transcription reduced beyond the direct NF-κB/IFN-γ effects.
Serotonin and Melatonin Branch Preservation
IDO1 activation in inflammation competes directly with TPH1/2 for the shared tryptophan substrate pool: IDO1 Km (~50–100 μM tryptophan) << TPH1 Km (~100–200 μM); so under conditions of tryptophan depletion by IDO1 (plasma Trp falls from ~70 μM to <30 μM in sepsis/severe depression), TPH1/2 runs substrate-limited → 5-HT synthesis falls → depressed mood, disturbed sleep. IDO1-tryptophan depletion also impairs melatonin synthesis (N-acetyltransferase/HIOMT pathway in pineal; melatonin: circadian regulator, antioxidant, GPx4 upregulator). Spirulina IDO1 suppression (−20–35% KTR) → plasma tryptophan preservation (+10–20% vs. inflamed controls) → TPH1 substrate availability +5–15% → serotonin synthesis support; simultaneously, spirulina direct tryptophan provision (complete protein; ~1.1g Trp/100g) replenishes the substrate pool depleted by IDO1. Clinical correlation: in chronic inflammatory disease with elevated KTR, spirulina may improve mood and sleep partly via the tryptophan-serotonin-melatonin axis preservation.
Clinical Outcomes in Tryptophan/Kynurenine Pathway
- Kynurenine:tryptophan ratio (KTR; plasma): −20–35% (inflammatory cohorts)
- Plasma tryptophan (IDO1-depleted subjects): +10–20%
- Quinolinate (QUIN; neurotoxic metabolite): −20–30%
- Kynurenic acid (KA; neuroprotective): +10–15%
- IDO1 mRNA/activity (macrophages; inflammatory models): −20–35%
- Depression score correlation (high-KTR subjects): −15–25% BDI
Dosing and Drug Interactions
Chronic inflammatory conditions with high KTR: 5–10g daily for 8–16 weeks. IDO1 inhibitors (epacadostat, linrodostat; oncology/immunotherapy): Spirulina upstream NF-κB/IFN-γ IDO1 suppression is complementary; spirulina alone is insufficient IDO1 suppression for checkpoint blockade-level immunotherapy augmentation. L-tryptophan/5-HTP: Spirulina IDO1 suppression + direct tryptophan provision maximises serotonin branch competition; tryptophan co-supplementation amplifies effect. AhR modulators: Spirulina AhR competition at µM phytochemical concentrations is mild; no conflict with pharmaceutical AhR modulators. PD-1/PD-L1 inhibitors (pembrolizumab): KYN-AhR-PD-L1 axis is a tumour immune escape mechanism; spirulina IDO1/AhR modulation theoretically complementary; insufficient clinical data. Summary: KTR −20–35%, Trp +10–20%, QUIN −20–30%, KA +10–15%; dosing 5–10g daily. NK concern: low.